Loading…
Based on limited metadata, HomeChoice Partners, Inc. received an FDA Warning Letter on April 9, 2020, regarding products classified as "Other" — indicating the violation does not fit standard device or drug categories. Without access to the full letter text or specific subject information, the exact nature of the compliance issues cannot be determined from the metadata provided. The issuing office is also not specified in the available information, limiting clarity on which regulatory division initiated the action. Additional documentation would be needed to identify the specific violations and products involved.